Insys Therapeutics
1333 S Spectrum Boulevard
Suite 100
Chandler
Arizona
85286
United States
Tel: 602-910-2617
Fax: 602-910-2627
Email: info@insysrx.com
180 articles about Insys Therapeutics
-
INSYS Reports Preliminary Estimated Revenues From Subsys For The Third Quarter 2016
10/13/2016
-
Former INSYS Sales Manager is Arrested in Opioid Kickback Scheme
9/30/2016
-
INSYS Initiates Hunt for a New CEO
9/21/2016
-
Attorney General Accuses INSYS of Deceptively Marketing and Selling Its Opioid Painkiller
8/26/2016
-
INSYS Reports Phase III Trial Of Sublingual Buprenorphine Spray Met Primary Endpoint In Patients With Moderate-To-Severe Postoperative Pain After Bunionectomy
8/24/2016
-
INSYS Announces First Patient Enrolled In Phase II Trial For The Treatment Of Cocaine Dependence Using Pharmaceutical Cannabidiol
8/18/2016
-
INSYS Reports Second Quarter 2016 Results
8/3/2016
-
INSYS To Report Second Quarter 2016 Results
7/20/2016
-
10 Biotech Stocks that Could Blow Up in Q3
7/6/2016
-
FDA Clears INSYS' Syndros
7/5/2016
-
Three Biotechs Face Near-Term FDA Decisions
3/22/2016
-
USPTO Declines To Institute All Inter Partes Review Petitions Filed By CFAD Of INSYS U.S. Patents Directed To SUBSYS (Fentanyl Sublingual Spray)
3/10/2016
-
Three Drugmakers Facing FDA Decisions This Quarter
3/10/2016
-
INSYS To Present At J.P. Morgan 34th Annual Healthcare Conference
12/30/2015
-
After Interviewing Current and Former Employees, Firm Releases Another Scathing Report on INSYS
12/10/2015
-
INSYS Responds to Allegations It Falsified Reports to Sell More of its Cancer Pain Treatment
12/4/2015
-
INSYS Therapeutics Intends to Spend $100 Million on Drug Projects in 2016
11/24/2015
-
INSYS Therapeutics CEO Steps Down, New Leader Appointed
11/5/2015
-
INSYS Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track Designation From FDA For The Treatment Of Opioid Intoxication Or Overdose
10/30/2015
-
INSYS Therapeutics Issues Statement On Its Use Of Specialty Pharmacies
10/27/2015